“IPO盛宴”强势回归

艾美达医药咨询
Jul 09, 2025

2025年,生物医药板块正上演一场“王者归来”。01科创板第五套标准重启2025年6月,科创板第五套上市标准的正式重启,通过明确且高标准的指引,为未盈利硬科技企业铺设了一条清晰的上市路径。其核心要求,如不低于40亿元的预计市值,至少有一项核心产品获准开展二期临床试验等,旨在筛选出真正具有技术突破和广阔商业前景的行业领军者。为市场树立了清晰的标杆,让优质企业能够更有信心地冲刺A股市场。2025年7月...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10